371 related articles for article (PubMed ID: 15714259)
1. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
[TBL] [Abstract][Full Text] [Related]
2. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer, osteoporosis and fracture risk.
Allain TJ
Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
8. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
10. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
11. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
12. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy.
Zhumkhawala AA; Gleason JM; Cheetham TC; Niu F; Loo RK; Dell RM; Jacobsen SJ; Chien GW
Urology; 2013 May; 81(5):1010-5. PubMed ID: 23490521
[TBL] [Abstract][Full Text] [Related]
15. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
16. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
17. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study.
Díaz Convalía EJ; Cano-García MDC; Miján-Ortiz JL; Arrabal-Martín M; Arrabal-Polo MÁ; Cózar-Olmo JM
Med Clin (Barc); 2017 Jun; 148(11):495-497. PubMed ID: 28256207
[TBL] [Abstract][Full Text] [Related]
20. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
